X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Overcoming challenges in effervescent dosage manufacturing

Content Team by Content Team
19th October 2021
in Drug Development, News
Overcoming challenges in effervescent dosage manufacturing

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

To improve the taste and stability of effervescent tablets and powders, BENEO presents galenIQ™ 721. This filler-binder enables pharmaceutical and nutraceutical manufacturers to target consumers that have difficulty swallowing standard tablets. As a non-hygroscopic, water-soluble and directly compressible excipient, galenIQ™ 721 also provides high content uniformity and production efficiency for effervescent applications.

Effervescent dosage forms offer distinct advantages compared with traditional tablets. For instance, many patients have problems swallowing tablets. Effervescent powders and tablets offer a more convenient way to deliver medicines or dietary supplements. They dissolve upon contact with water to release carbon dioxide and create a drink. In addition, they can be used to formulate pharmaceuticals that are difficult to digest, that cause stomach or esophageal irritation or that rely on a rapid onset of action, such as analgesics.

However, manufacturing effervescent dosage forms is often challenging. To produce highly stable tablets, a non-hygroscopic, direct compression filler-binder such as galenIQ™ 721 is needed. It ensures high content uniformity and facilitates production. BENEO’s excipient has a sugar-like taste profile, a pleasant mouthfeel and can enhance the palatability of effervescent formulations. Furthermore it is non-cariogenic and therefore is both sweet and tooth-friendly.

Dr Maj-Britt Cepok, Head of Business Development, Pharma, BENEO, comments: “Fizzy tablets are ideally suited to administer a wide range of light-, oxygen- and other sensitive active ingredients and those that require a large dose. In addition, effervescent preparations are more appealing to consumers than traditional dosage forms. galenIQ™ 721 helps manufacturers to tap into this market and enhance their development programs.”

About galenIQ™
BENEO is part of the Südzucker Group and a member of the International Pharmaceutical Excipients Council (IPEC). The company produces galenIQ™ (Isomalt Ph. Eur., BP, USP-NF, JP), a multifunctional range of water-soluble filler-binders according to cGMP conditions for pharmaceutical excipients. galenIQ™ is available in a wide variety of median particle sizes, morphologies and solubilities and
therefore is readily used in solid and liquid dosage forms such as tablets, sachets, effervescents, lozenges and syrups. It is physically and chemically stable, non-hygroscopic and enhances the palatability of the final form.

Previous Post

Fujitsu and Aichi Cancer Center Develop AI System to Offer Patients Personalized Cancer Treatment

Next Post

Ophthalmic Company Implandata Awarded as Top 12 Healthcare Innovator at Medica, World Forum for Medicine

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Ophthalmic Company Implandata Awarded as Top 12 Healthcare Innovator at Medica, World Forum for Medicine

Ophthalmic Company Implandata Awarded as Top 12 Healthcare Innovator at Medica, World Forum for Medicine

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In